Assessment of autoantibodies to meningioma in a population-based study

American Journal of Epidemiology

Volumn 177, Issue 1, 2013, Pages 75-83

  Wiemels, Joseph L ^a   Bracci, Paige M ^a   Wrensch, Margaret ^a   Schildkraut, Joellen ^b   Bondy, Melissa ^c   Pfefferle, Jon ^a   Zhou, Mi ^a   Sison, Jennette ^a   Calvocoressi, Lisa ^d   Claus, Elizabeth B ^e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

autoantibodies; brain neoplasms; genetics; immunologic factors; meningioma; neurosurgery; risk factors

Indexed keywords

AUTOANTIBODY; ENOLASE; ENOLASE 1; NK TUMOR RECOGNITION PROTEIN; NUCLEAR MITOTIC APPARATUS PROTEIN 1; PROTEIN; UNCLASSIFIED DRUG;

ABNORMALITY; ALLERGY; ANTIBODY; ANTIGEN; BRAIN; DISEASE TREATMENT; ETIOLOGY; GENETICS; IMMUNE SYSTEM; NERVOUS SYSTEM DISORDER; PROTEIN; RISK FACTOR; SERUM; TUMOR; VIRUS;

ADULT; ALLERGY; ANTIBODY SCREENING; ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; MAJOR CLINICAL STUDY; MALE; MENINGIOMA; MULTICENTER STUDY; POPULATION BASED CASE CONTROL STUDY; RISK FACTOR;

ADULT; AGED; ANTIGENS, NUCLEAR; AUTOANTIBODIES; DNA-BINDING PROTEINS; ECZEMA; FEMALE; HUMANS; HYPERSENSITIVITY; MALE; MENINGIOMA; MIDDLE AGED; NUCLEAR MATRIX-ASSOCIATED PROTEINS; PHOSPHOPYRUVATE HYDRATASE; RECEPTORS, IMMUNOLOGIC; SEX FACTORS; SMOKING; SOCIOECONOMIC FACTORS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS; UNITED STATES;

UNITED STATES;

EID: 84871749805     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kws221     Document Type: Article

References (22)

1. Central Brain Tumor Registry of the United States. 2009-2010 CDTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in Eighteen States in 2002-2006. Hisdale, IL: Central Brain Tumor Registry of the United States; 2009.
2. Claus EB, Bondy ML, Schildkraut JM, et al. Epidemiology of intracranial meningioma. Neurosurgery. 2005;57(6):1088-1095.
3. Wiemels J, Wrensch M, Claus EB. Epidemiology and etiology of meningioma. J Neurooncol. 2010;99(3):307-314.
4. Wiemels JL, Wrensch M, Sison JD, et al. Reduced allergy and immunoglobulin E among adults with intracranial meningioma compared to controls. Int J Cancer. 2011; 129(8):1932-1939.
5. Schoemaker MJ, Swerdlow AJ, Hepworth SJ, et al. History of allergic disease and risk of meningioma. Am J Epidemiol. 2007;165(5):477-485.
6. Brenner AV, Linet MS, Fine HA, et al. History of allergies and autoimmune diseases and risk of brain tumors in adults. Int J Cancer. 2002;99(2):252-259.
7. Ryan P, Lee MW, North B, et al. Risk factors for tumors of the brain and meninges: results from the Adelaide Adult Brain Tumor Study. Int J Cancer. 1992;51(1):20-27.
8. Schlehofer B, Blettner M, Preston-Martin S, et al. Role of medical history in brain tumour development. Results from the International Adult Brain Tumour Study. Int J Cancer. 1999;82(2):155-160.
9. Schwartzbaum J, Jonsson F, Ahlbom A, et al. Cohort studies of association between self-reported allergic conditions, immune-related diagnoses and glioma and meningioma risk. Int J Cancer. 2003;106(3):423-428.
10. Wigertz A, Lonn S, Schwartzbaum J, et al. Allergic conditions and brain tumor risk. Am J Epidemiol. 2007;166(8):941-950.
11. Kobold S, Lutkens T, Cao Y, et al. Autoantibodies against tumor-related antigens: incidence and biologic significance. Hum Immunol. 2010;71(7):643-651.
12. Comtesse N, Zippel A, Walle S, et al. Complex humoral immune response against a benign tumor: frequent antibody response against specific antigens as diagnostic targets. Proc Natl Acad Sci USA. 2005;102(27):9601-9606.
13. Keller A, Ludwig N, Comtesse N, et al. Combining gene expression signatures and autoantibody profiles in human meningioma. Gene Ther. 2009;16(2):184-189.
14. Keller A, Ludwig N, Comtesse N, et al. A minimally invasive multiple marker approach allows highly efficient detection of meningioma tumors. BMC Bioinformatics. 2006;7:539. (doi:10.1186/1471-2105-7-539).
15. Ludwig N, Keller A, Heisel S, et al. Novel immunogenic antigens increase classification accuracy in meningioma to 93.84%. Int J Cancer. 2011;128(6):1493-1501.
16. Khan IH, Kendall LV, Ziman M, et al. Simultaneous serodetection of 10 highly prevalent mouse infectious pathogens in a single reaction by multiplex analysis. Clin Diagn Lab Immunol. 2005;12(4):513-519.
17. Cowppli-Bony A, Bouvier G, Rue M, et al. Brain tumors and hormonal factors: review of the epidemiological literature. Cancer Causes Control. 2011;22(5):697-714.
18. McClelland EE, Smith JM. Gender specific differences in the immune response to infection. Arch Immunol Ther Exp (Warsz). 2011;59(3):203-213.
19. Tanriverdi F, Silveira LF, MacColl GS, et al. The hypothalamic-pituitary- gonadal axis: immune function and autoimmunity. J Endocrinol. 2003;176(3):293-304.
20. Shames RS. Gender differences in the development and function of the immune system. J Adolesc Health. 2002; 30(4 suppl):59-70.
21. Cutolo M, Sulli A, Seriolo B, et al. Estrogens, the immune response and autoimmunity. Clin Exp Rheumatol. 1995; 13(2):217-226.
22. Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989;81(24):1879-1886.